Journal of Carcinogenesis & Mutagenesis

Leticia Batista Azevedo Rangel

Publications

• Review Article
  Metformin and mTOR Inhibitors: Allies against Ovarian and Breast Cancers
  Author(s): Isabella dos Santos Guimarães, Nayara Gusmão Tessarollo, Diandra Zipinotti dos Santos, Marcele Lorentz Mattos de Souza, Taciane Barbosa Henriques, Ian Victor Silva and Leticia Batista Azevedo RangelIsabella dos Santos Guimarães, Nayara Gusmão Tessarollo, Diandra Zipinotti dos Santos, Marcele Lorentz Mattos de Souza, Taciane Barbosa Henriques, Ian Victor Silva and Leticia Batista Azevedo Rangel
  
  Cancer is one of the leading causes of death worldwide. Every year 8.2 million people die from the disease. In this context, breast and ovarian cancer are the most incidental among women. Elucidation of cell growth pathways and the observation that these pathways are altered in human cancer have encouraged the search for specific inhibitors. The phosphatidylinositol-3cinase (PI3K)/Protein kinase b (AKT)/Mammalian Target of Rapamycin (mTOR) is an important pathway involved in cell growth, tumorigenesis, cell invasion, and resistance to therapies. This pathway is often activated in breast and ovarian cancers and the deregulation of its signaling can contribute to tumor growth, angiogenesis and metastasis. Metformin is one of the most commonly prescribed antidiabetic drugs in the world whose anticancer effects, mediated by reduced mTOR signaling, have become notable. Therefore, this revi.. View More»
  DOI: 10.4172/2157-2518.1000299

  Abstract PDF